Steve Tuplin/LinkedIn
Dec 6, 2025, 11:50
Steve Tuplin on Roche’s Mission at ASH25
Steve Tuplin, VP, Global Disease Area Head – Hematology and ai Oncology at Roche, shared on LinkedIn:
”Next stop: Orlando!
While many head there for the thrill rides, we are heading to ASH25 for a different kind of excitement: the breakthroughs shaping the future of haematology.
We are looking forward to sharing how our broad portfolio is evolving to meet the real-world needs of patients and the healthcare system.
It’s not about magic; it’s about our unwavering commitment to raising the therapeutic bar and delivering innovation that truly matters.
I’m excited to catch up with those of you attending.
Let me know—what is top of your list for this year?”
All from ASH25 featured in Hemostasis Today.
-
Mar 16, 2026, 07:26James Crowley, Professor of Medicine emeritus at Brown University, posted on LinkedIn:
-
Mar 15, 2026, 15:55Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 2
-
Mar 15, 2026, 14:09Abdul Mannan: A Red Eye, a Blood Clot, and Ibrutinib – The Clinical Tightrope
-
Mar 15, 2026, 14:02Denise M: Precision Hemostasis in Patient Blood Management
-
Mar 15, 2026, 13:57Abdulrahman Nasiri: D14 Bone Marrow Biopsy in AML Induction in the Era of Targeted Therapies
-
Mar 15, 2026, 13:52Valentin Ortiz-Maldonado: High-Impact Innovation in CAR-T Therapy Can Emerge From Academic Programmes
-
Mar 15, 2026, 13:45Tareq Abadl: Has Anyone Here Ever Taken an ALP Test Before?
-
Mar 14, 2026, 21:30Ayman Elbadawi: Why Does Stent Thrombosis Still Occur? Insights from the NCDR Data
-
Mar 14, 2026, 20:03Edward Adomako: Recognizing Thrombotic Thrombocytopenic Purpura as A Life-Threatening Emergency